Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing Vaccine

N/ACompletedNCT02901990

Jiangsu Province Centers for Disease Control and Prevention7,901 enrolled

Overview

This study was aimed to conduct a 3-year perspective study to observe the immunological effect of one-dose mumps-containing vaccine, monitor the incidence of mumps in vaccinated population aged 3-7 years，and provide basis for adjusting MMR immunization strategy in Jiangsu province, China.

in 3-7 years old children with high risk of mumps, epidemiological investigation of the serum IgG antibody level were conducted, and then a prospective observational cohort was established in the population with a history of mumps vaccination, and the incidence of mumps in each antibody level group will be observed, the relationship between different antibody levels and the incidence after mumps vaccinated were analyzed, to explore attenuation of mumps IgG antibody levels in the body,S79 vaccine strain against F genotype mumps' antigenic cross-reactivity and the protective effect of antibodies.

Study Type

OBSERVATIONAL

Enrollment

7,901

Conditions

Parotid Gland Infection Fever

Eligibility

Sex: ALLMin age: 3 YearsMax age: 7 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Children aged 3-7 years old; 2. local resident children living at least 3 months; 3. physical health, has been vaccinated at least once a dose of MuV Exclusion Criteria: 1. did not administer MuV; 2. refused to collect venous blood; 3. have been infected with mumps; 4. have serious illness or other reasons should not participate in the study after clinical evaluation

Locations (6)

wujin district CDC

Changzhou, Jiangsu, China

lianshui county CDC

Huaian, Jiangsu, China

ganyu district CDC

Lianyungang, Jiangsu, China

gaogang district CDC

Taizhou, Jiangsu, China

Outcomes

Primary Outcomes

to describe the sero-prevalence in specific age groups following an active surveillance of vaccinated subjects in each year

Time frame: 3 years

Secondary Outcomes

to describe wane immunity of IgG antibody to mumps virus in specific age groups following an active surveillance of vaccinated subjects in each year

Time frame: 3 years

To characterize the incidence of mumps in specific age groups following an active surveillance of vaccinated subjects in each year

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.